342 related articles for article (PubMed ID: 33395045)
1. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4.
Parvini S; Majidpoor J; Mortezaee K
Pathol Res Pract; 2023 Jul; 247():154583. PubMed ID: 37267723
[TBL] [Abstract][Full Text] [Related]
5. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
6. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Cowey CL; Lao CD; Schadendorf D; Dummer R; Smylie M; Rutkowski P; Ferrucci PF; Hill A; Wagstaff J; Carlino MS; Haanen JB; Maio M; Marquez-Rodas I; McArthur GA; Ascierto PA; Long GV; Callahan MK; Postow MA; Grossmann K; Sznol M; Dreno B; Bastholt L; Yang A; Rollin LM; Horak C; Hodi FS; Wolchok JD
N Engl J Med; 2015 Jul; 373(1):23-34. PubMed ID: 26027431
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
Pistillo MP; Carosio R; Grillo F; Fontana V; Mastracci L; Morabito A; Banelli B; Tanda E; Cecchi F; Dozin B; Gualco M; Salvi S; Spagnolo F; Poggi A; Queirolo P
Clin Immunol; 2020 Jun; 215():108428. PubMed ID: 32344017
[TBL] [Abstract][Full Text] [Related]
9. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
[TBL] [Abstract][Full Text] [Related]
10. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
11. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
12. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Koguchi Y; Iwamoto N; Shimada T; Chang SC; Cha J; Curti BD; Urba WJ; Piening BD; Redmond WL
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34620702
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
14. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
16. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
17. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
[TBL] [Abstract][Full Text] [Related]
18. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
19. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
